MAK Capital One’s Achillion Pharmaceuticals ACHN Stock Holding History

MAK Capital One’s Portfolio ACHN Stock Details ACHN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-6,642,814	Closed	-$40.1M	–	11
2019 Q4	$40.1M	Sell	6,642,814 -286,839	-4%	-$1.66M	13.12%	4
2019 Q3	$24.9M	Hold	6,929,653	–	–	9.97%	4
2019 Q2	$18.6M	Hold	6,929,653	–	–	8.81%	4
2019 Q1	$20.5M	Buy	6,929,653 +1,738,053	+33%	+$4.27M	11.06%	3
2018 Q4	$8.26M	Buy	5,191,600 +3,245,493	+167%	+$9.17M	4.47%	3
2018 Q3	$7.16M	Buy	+1,946,107	New	+$5.8M	2.34%	5

MAK Capital One's ACHN Position: Q1 2020 in Review

MAK Capital One sold out of Achillion Pharmaceuticals (ACHN) in Q1 2020, closing a stake of 6,642,814 shares — an estimated $40.1M sold.

MAK Capital One first reported a position in ACHN in Q3 2018 and held it in 6 quarters. The position peaked at $40.1M in Q4 2019. 0 funds tracked by Wall St. Rank hold ACHN as of Q1 2020.

MAK Capital One reported no remaining Achillion Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
MAK Capital One sold 6,642,814 Achillion Pharmaceuticals shares in Q1 2020, an estimated $40.1M.
MAK Capital One first reported a position in Achillion Pharmaceuticals in Q3 2018 and held it in 6 quarters.
MAK Capital One's Achillion Pharmaceuticals position peaked at $40.1M in Q4 2019.
0 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q1 2020.

Based on MAK Capital One's 13F filing for Q1 2020, filed 15 May 2020.